Navigation Links
ANA773 in Medical News

Anadys Pharmaceuticals to Present at the Citi Biotech Day

...interferons that acts via the TLR7 pathway. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Statements in... of future results, and Anadys cannot provide any assurances that ANA598 or ana773 will not have unforeseen safety issues, will have favorable results in ongo...

Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights

... of the first quarter of 2009. ana773 ana773 is an oral prodrug of a small molecule inducer of ...t led to no adverse findings. Anadys is exploring ana773 in two early clinical studies, one in HCV patients...

Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results

...r and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Statement...of future results, and Anadys cannot provide any assurances that ANA598 and ana773 will not have unforeseen safety issues, will have favorable results in futu...

Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference

...nd an update on its clinical programs: ANA598 and ana773 in hepatitis C and ana773 in cancer. Additionally, Dr. Worland will par...7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor...

Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study

...tentially complementary agents: ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Statements in this press release that are not strictly historical in nature constitute "forward...

Anadys Pharmaceuticals to Present at Bio Investor Forum

...or and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Statements in this p...of future results, and Anadys cannot provide any assurances that ANA598 and ana773 will not have unforeseen safety issues, will have favorable results in futu...
ANA773 in Medical Technology

Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor Activity of Natural Killer Cells

Poster Presentation on April 17, 2007 at AACR SAN DIEGO, April 17 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. presented data from an in vitro study showing that the active metabolite of ANA773 promotes natural killer (NK) cell-mediated anti-tumor response by inducing cytokine secretion,...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

...-nucleoside polymerase inhibitor and ANA773, an oral inducer of endogenous interferons that acts via the TLR7 pathway. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Statements in this press release that are not strictly historical in nature constit...

ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients

...entially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Statements in this press release that are not strictly historical in nature cons...

Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers

...or and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Statements in this p...of future results, and Anadys cannot provide any assurances that ANA598 and ana773 will not have unforeseen safety issues, will have favorable results in futu...

Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference

...Anadys and its three clinical programs: ANA598 and ana773 in hepatitis C and ana773 in cancer. The presentation will be simultaneous...R7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Stateme...

Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients

...tentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Statements in this press release that are not strictly historical in nature constitute "forward...

Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV

...anded HCV Development Presence Includes ANA598 and ana773 Acting via Independent but Potentially Co...l patients in a separate Phase I clinical trial of ana773 in oncology that is ongoing under an IND in the Un...ction of interferon-alpha dependent responses when ana773 is dosed every other day over 13 weeks, have convi...

Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598

...encement of dosing in a Phase I clinical trial for ana773 in cancer patients in February and this study of A...ve important clinical milestones in the ANA598 and ana773 programs; and (v) expectations regarding the evolu...adys cannot provide any assurances that ANA598 and ana773 will not have unforeseen safety issues, will have ...
ANA773 in Biological News

Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference

...ew of Anadys and its clinical programs: ANA598 and ana773 in hepatitis C and ana773 in cancer. The presentation will be simultane...7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor...
ANA773 in Biological Technology

Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today that it has initiated dosing ANA773 in patients chronically infected with hepatitis C virus (HCV) in Part B of a two-part protocol designed to test ANA773 in both healthy volunteers and H...

Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients

SAN DIEGO, Feb. 28 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced that patient dosing has commenced in a Phase I study of ANA773, the company's oral TLR7 agonist prodrug, in patients with advanced solid tumors. This first-in-human trial is a safety and ...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

...imarily attributable to a $1.3 million decrease in ana773 development costs partially offset by $0.5 million...e strategic restructuring initiated in June 2009. ana773 development costs during the second quarter of 200...f hepatitis C. During the second quarter of 2008, ana773 development costs were primarily driven by the now...

Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results

...the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ana773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval. Risk fa...

Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598

... Company intends to suspend further development of ana773 and is reducing its workforce by approximately 40%...titis C and oncology, Anadys intends to manage the ana773 programs as potential out-licensing opportunities.... plans, its focus of operations, management of its ana773 programs, its plans regarding the planned ANA598 P...

Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights

...ter of 2008, partially offset by a decrease in our ana773 development costs. The ANA598 development costs w...s which were initiated during September 2008. Our ana773 development costs during the three months ended Ma...ha, telaprevir and PSI-6130. ana773 ...

Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results

...interferons that acts via the TLR7 pathway. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Stat... of future results, and Anadys cannot provide any assurances that ANA598 or ana773 will not have unforeseen safety issues, will have favorable results in ongo...

Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry

...ew of Anadys and its clinical programs: ANA598 and ana773 in hepatitis C and ana773 in cancer. The corporate presentation will be... the TLR7 pathway. The Company is also developing ana773 for the treatment of cancer. Safe Harbor...

ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection

...entially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Harbor Statement Statements in this press release that are not strictly historical in natu...

Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference

...nadys and its three clinical programs: ANA598 and ana773 in hepatitis C and ana773 in cancer. The presentation will be simul...7 agonist prodrug. The Company is also developing ana773 for the treatment of cancer. Safe Har...
Other Tags
(Date:7/9/2014)... common type of lung cancer, researchers have uncovered mutations ... forming tumors. The new knowledge may expand treatments for ... already are available or are in clinical trials. , ... The Cancer Genome Atlas (TCGA), including researchers at Washington ... School and other institutions, studied tumors from 230 patients ...
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective ... immunocompromised patients. This is the result of a study ... Center for Women,s Gastrointestinal Medicine at The Women,s Medicine ... online in advance of print in the American ... or C. diff , has increased to epidemic ...
(Date:7/9/2014)... N.Y. Although feelings are personal and subjective, ... code that objectively represents emotions across different senses, ... by Cornell University neuroscientist Adam Anderson. , "We ... the orbitofrontal cortex, an area of the brain ... code which captures an individual,s subjective feeling," says ...
(Date:7/9/2014)... from Montefiore Medical Center and the ... will present new findings at the Alzheimer,s Association International ... in Copenhagen, Denmark. Data from the four abstracts will ... normality to mild cognitive impairment and dementia. The research ... established in 1980 to examine healthy brain aging as ...
(Date:7/9/2014)... have a reputation for being highly toxic, but when used ... being found to offer potential health benefits in a range ... A new compound (AP39), designed and made at the University ... targeting delivery of very small amounts of the substance to ... in Exeter have already found that the compound protects mitochondria ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Rotten egg gas holds key to healthcare therapies 2
(Date:7/9/2014)... the oils produced by algae may offer a low-cost ... optimization of cost effective strategies for large-scale algae cultivation, ... Energy has developed an innovative solution to the challenge ... in Industrial Biotechnology , a peer-reviewed journal from ... on the Industrial Biotechnology website . ...
(Date:7/9/2014)... Ill. With over 100 diseases that can attack ... top of the most wanted list? University of Illinois ... that more research is needed on the fungus that ... with cool, damp growing conditions but Macrophomina phaseolina ... and dry drought conditions. , "As the climate continues ...
(Date:7/9/2014)... a sparrow-sized fossil from China challenges the commonly held ... gained the ability to fly. The birdlike fossil is ... rather the remains of a tiny tree-climbing animal that ... Dinosaur Museum in Blanding, Utah, and Alan Feduccia of ... Springer,s Journal of Ornithology . , The fossil ...
Breaking Biology News(10 mins):Controlling contamination in open algae ponds for biofuels 2Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3Researchers declassify dinosaurs as being the great-great-grandparents of birds 2
Other Contents